Anticoagulation in device-detected atrial fibrillation with or without vascular disease: a combined analysis of the NOAH-AFNET 6 and ARTESiA trials.
Renate B SchnabelJuan Benezet-MazuecosNina FluschnikWilliam F McIntyreAlexander FierenzShun Fu LeeAndreas GoetteDan AtarEmanuele BertagliaAlexander P BenzGrigoris ChlouverakisDavid H BirnieWolfgang DichtlCarina Blomstrom-LundqvistAlan John CammJulia W ErathEmmanuel N SimantirakisValentina KutyifaGregory Y H LipPhilippe MaboEloi MarijonLena RivardUlrich SchottenMarco AlingsSusanne SehnerTobias ToennisCecilia LindePanos VardasChristopher B GrangerAntonia ZapfRenato D LopesJeffrey S HealeyPaulus F KirchhofPublished in: European heart journal (2024)
Patients with DDAF and vascular disease are at higher risk of stroke and cardiovascular events and may derive a greater benefit from anticoagulation than patients with DDAF without vascular disease.